Phase 1 N=65 NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)
Neuroblastoma
Primary: MTD/RP2D Determination A1 — 0; 0; 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=6 A Safety Study of the Auditory Brainstem Implant for Pediatric Profoundly Deaf Patients
Profound Bilateral Deafness Due to · Bilateral Cochlear Aplasia · Bilateral Cochlear Nerve Deficiency
Primary: Primary Endpoint — 6 Participants
Phase 1 N=11 Transcranial Magnetic Stimulation and Constraint Induced Language Therapy for Alzheimer Disease
Alzheimer Disease
Primary: Change in WAB-AQ Score — -1.7; -.1 score on a scale — p=<.05
Phase 1 N=3 Post-transplant Flotetuzumab for AML
Leukemia, Myeloid, Acute
Primary: Number of Participants With Dose-limiting Toxicities to Determine Maximum Tolerated Dose (MTD) of Flotetuzumab in Patients With Relapsed/Refractory AML Following…
Phase 1 N=12 Ketamine Tolerated Dose for Postpartum Depression and Pain After Cesarean Delivery (PREPARE 1)
Pain, Postoperative · Depression, Postpartum
Primary: Maximum Tolerated Dose of Ketamine — 3; 3; 3; 3 Participants
Phase 1 N=14 A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 706321 in the Blood
Healthy
Primary: Area Under the Concentration-time Curve of BI 706321 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) — 60.99; 133.45 Hours * nanomoles / liter
Phase 1 N=24 A Study to Investigate the Safety and Pharmacokinetics of Lebrikizumab in Healthy Chinese Participants
Healthy
Primary: Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) — 10; 10; 3; 0 participants
Phase 1 N=41 A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer
Neuroendocrine Prostate Cancer
Primary: Number of Participants Who Experienced One or More Treatment-emergent Adverse Events (TEAEs) — 40 Participants
Phase 1 N=30 Evaluation of Vamorolone Mineralocorticoid Receptor Antagonism in Healthy Subjects
Pharmacodynamic
Primary: Determination of the Ratio of Sodium to Potassium (Na/K) in Urine — 1.12929; 0.98207; 1.04238; 0.54902 log10(10*Na/K)
Phase 1 N=5 A Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]INCB099280 in Healthy Male Participants
Healthy Participants
Primary: Total Recovery (Urine + Feces) of the Administered Radioactivity — 83.2 percentage of radioactivity
Phase 1 N=53 A Study of LY3451838 in Healthy Participants
Healthy
Primary: Number of Participants With Any Treatment Emergent Adverse Event — 4; 5; 4; 6 Participants
Phase 1 N=16 A Safety Study of LY3526318 in Healthy Participants
Healthy
Primary: Part A - SAD, Pharmacokinetics (PK): Area Under the Concentration Time Curve From Time 0 to Infinity (AUC 0-∞) of LY3526318 — 147978; 131271; 137814; 76902…
Phase 1 N=14 A Study of MK-2060 in Participants With Chronic and/or End-Stage Kidney Disease (MK-2060-011)
End-Stage Renal Disease · End-Stage Kidney Disease · Kidney Failure, Chronic
Primary: Part 1: Number of Participants Who Experience One or More Bleeding Related Adverse Events (AE) — 0; 0 Participants
Phase 1 N=54 A Study of Lispro Formulations in Healthy Participants
Healthy Volunteers
Primary: Part A and Part B: Pharmacokinetics (PK): Area Under The Concentration Curve Zero to Infinity (AUC[0-∞]) — 916; 957; 1020; 972 picomole*hour/Liter (pmol*hr/L) — p=0.2071
Phase 1 N=90 Study to Evaluate the Safety, Tolerability and Immunogenicity of Three Doses of GBS Vaccine in Elderly Participants
Group B Streptococcal Infections
Primary: Safety and Tolerability of the GBS-NN/NN2 Vaccine for 4 Weeks After Each Dose of Vaccine — 23; 21; 5; 10 Participants